S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

计划入组 7 人 · 首次发布于 2019 年 10 月 28 日

The Prevalence of RYR1-related Disease

计划入组 2,000 人 · 首次发布于 2025 年 1 月 24 日

Antioxidant Therapy in RYR1-Related Congenital Myopathy

计划入组 63 人 · 首次发布于 2015 年 2 月 13 日

99mTc-HYNIC (Tyr3)-octreotide

C₆₁H₈₁ClN₁₅O₁₇S₂Tc

[18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate

[18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues(Imperial College London)

Biocartis Receives FDA Approval for First Fully Automated Companion Diagnostic Test for Colorectal Cancer